Ludger Klimek, Ulrike Förster-Ruhrmann, Heidi Olze, Achim G Beule, Adam M Chaker, Jan Hagemann, Tilman Huppertz, Thomas K Hoffmann, Stefan Dazert, Thomas Deitmer, Sebastian Strieth, Holger Wrede, Wolfgang W Schlenter, Hans-Jürgen Welkoborsky, Barbara Wollenberg, Sven Becker, Fredericke Bärhold, Felix Klimek, Ingrid Casper, Jaron Zuberbier, Claudia Rudack, Mandy Cuevas, Constantin A Hintschich, Orlando Guntinas-Lichius, Timo Stöver, Christoph Bergmann, Pascal Werminghaus, Oliver Pfaar, Jan Gosepath, Moritz Gröger, Caroline Beutner, Martin Laudien, Rainer K Weber, Tanja Hildebrand, Anna S Hoffmann, Claus Bachert
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and sinuses. Eosinophilic inflammation is described as a common endotype. The anti-IL-5 antibody mepolizumab was approved in November 2021 as an add-on therapy to intranasal glucocorticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps when systemic glucocorticosteroids or surgery do not provide adequate disease control...
2024: Allergologie Select